Clinical Psychiatry • October 18, 2026
Psilocybin-Assisted Therapy for Treatment-Resistant Depression: Phase 2/3 Trial Analysis
Clinical trial outcomes demonstrate that 25mg psilocybin combined with psychological support produces significant, sustained HAM-D and MADRS depression score reductions.
The Challenge of Treatment-Resistant Depression (TRD)
Over 30% of patients diagnosed with Major Depressive Disorder (MDD) fail to respond to two or more conventional pharmaceutical antidepressant trials, leaving them with persistent disability and high relapse rates.
Clinical Protocols and Outcome Metrics
In rigorous double-blind randomized trials, a single 25mg dose of pharmaceutical-grade psilocybin demonstrated statistically significant reductions in MADRS (Montgomery-Åsberg Depression Rating Scale) scores within 24 hours compared to 1mg controls.
Durability of Remission and Long-Term Neuroplastic Reset
Over 45% of participants maintained complete clinical remission at 12 weeks post-treatment without daily medication, driven by sustained neural network rewiring and psychological integration.